This site uses cookies to ensure the best viewing experience for our readers.
BioLineRx’s Flagship Pancreas Cancer Drug Receives Orphan Drug Status in Europe

Brief

BioLineRx’s Flagship Pancreas Cancer Drug Receives Orphan Drug Status in Europe

The clinical stage company’s drug received a similar designation in the U.S. last year

Tzally Greenberg | 10:21  15.01.2020
Nasdaq and Tel Aviv-listed BioLineRx Ltd. has received orphan drug designation from the European Medicines Agency (EMA) for its pancreatic cancer drug candidate, Motixafortide (BL-8040), the company announced Tuesday. BioLineRx’s drug received the same status from the U.S. Food and Drug Administration (FDA) in 2019. The clinical stage drug company was founded in 2003 and is currently traded at a market capitalization of $26.7 million.

BioLineRx CEO Philip Serlin. Photo: pr BioLineRx CEO Philip Serlin. Photo: pr BioLineRx CEO Philip Serlin. Photo: pr

share on facebook share on twitter share on linkedin share on whatsapp share on mail

TAGS